PR Newswire Clinical TrialsOriginal article
XtalPi Advances Hair Loss Drug Program into IND-Enabling Studies
Positive
AI Analysis
Summary
XtalPi has advanced a proprietary hair loss drug program into IND-enabling studies, targeting the lactate-autophagy pathway to reactivate quiescent hair follicle stem cells. In mouse models, the candidate demonstrated hair-growth effects comparable to 5% topical minoxidil at 1/100 of the concentration.
Outcome Details
Advancement into IND-enabling studies
Importance:4/10
Sentiment:
0.70
hair losspreclinicalIND-enabling studieslactate-autophagy pathwayhair follicle stem cells
Read the original article
Published by PR Newswire Clinical Trials on October 2, 2026 10:33 PM